Cary Street Partners Financial LLC Has $5.07 Million Holdings in Amgen Inc. $AMGN

Cary Street Partners Financial LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 15.3% during the fourth quarter, Holdings Channel reports. The fund owned 15,478 shares of the medical research company’s stock after purchasing an additional 2,057 shares during the period. Cary Street Partners Financial LLC’s holdings in Amgen were worth $5,066,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC increased its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after acquiring an additional 416 shares in the last quarter. Finally, Ieq Capital LLC increased its position in Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after acquiring an additional 2,611 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Argus reduced their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. UBS Group upped their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Royal Bank Of Canada increased their price objective on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Finally, Guggenheim lowered their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $355.19.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Amgen Trading Down 1.0%

AMGN opened at $335.94 on Wednesday. The firm has a 50 day simple moving average of $343.92 and a 200 day simple moving average of $345.13. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a market cap of $181.30 billion, a price-to-earnings ratio of 23.38, a price-to-earnings-growth ratio of 3.41 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.